Luneri

Ashwagandha clinical brief

Ashwagandha

Dossier liveB

Hormonal

HormonalDossier-backedDietary Supplement

Compare alternatives

Evidence strength

High confidence

11 meta-analyses - 47 RCTs - 94 tracked studies

What it is for

Stress and anxiety reduction in healthy adults

The clearest current human use case based on dose, outcomes, and clinical coverage.

What moves

Highest-signal biomarkers

Human linked

Fasting glucose

Glycemic control

Decrease

Grade B

HbA1c

Glycemic control

Decrease

Grade B

Lipid response

Decrease

Grade B

Research signal

Top caution

Drug interaction

Ashwagandha increases serum T3 and T4 levels in clinical trials via thyroid stimulation; additive effect with exogenous thyroid hormone replacement may precipitate hyperthyroidism or thyrotoxicosis

Evidence index

Authored product-registry confidence score

Meta-analyses

Pooled human evidence

RCTs

Randomized clinical trials

Tracked studies

Studies currently mapped to this dossier

Clinical memoHigh confidence

Executive summary

Immediate brief

Ashwagandha is a Hormonal with its clearest current use in Stress and anxiety reduction in healthy adults.

High confidence human evidence supports the brief, anchored by 94 tracked studies, 11 meta-analyses, 47 RCTs and the most reliable movement in Fasting glucose, HbA1c, TC.

Ashwagandha increases serum T3 and T4 levels in clinical trials via thyroid stimulation; additive effect with exogenous thyroid hormone replacement may precipitate hyperthyroidism or thyrotoxicosis Ashwagandha increases serum T3 and T4 levels in clinical trials via thyroid stimulation; additive effect with exogenous thyroid hormone replacement may precipitate hyperthyroidism or thyrotoxicosis Hedge effect size estimates for European/North American patients; prefer independent replication data where available

Anchor decision

Stress and anxiety reduction in healthy adults

Best current human use case

Confidence

High confidence

11 meta-analyses - 47 RCTs - 94 tracked studies

How to use this brief

1. Orient

Use the overview tab to understand mechanism, safety, scope, and where the current evidence still has blind spots.

2. Pressure-test

Move into evidence and biomarkers once the memo already makes sense, so the tables confirm or challenge the narrative rather than replace it.

3. Operationalize

Finish with dosing and PGx when the compound still looks useful and you are deciding whether it belongs in a real protocol.

AshwagandhaDossier liveBPrimary useStress and anxiety reduction in healthy adults

CautionDrug interaction

Major warning

Pregnancy (all trimesters)

Hedge effect size estimates for European/North American patients; prefer independent replication data where available

Overview

Clinical posture

Start with mechanism and safety, then move into scope, synergies, and the open questions that still matter before going deeper into tables.

Primary signal

Mechanism summary

Read this as the shortest defensible explanation for why the compound belongs in the conversation at all.

HPA axis modulation - withanolides suppress CRH-driven ACTH secretion and attenuate cortisol output from adrenal cortex; adaptogenic normalization of glucocorticoid receptor sensitivity proposed via heat shock protein modulation

NF-kB inhibition - withanolides (primarily withaferin A) prevent IkB phosphorylation/degradation, blocking p50/p65 nuclear translocation; reduces downstream TNF-alpha, IL-1beta, IL-6, COX-2 transcription; interdependence with oxidative stress: H2O2-driven NF-kB activation countered by ashwagandha antioxidant activity

NRF2-ARE pathway activation - withanolides activate NRF2 signaling, upregulating antioxidant enzymes (SOD, catalase, GSH peroxidase) and increasing GSH/GSSG ratio; reduces MDA and 8-OHdG; 8 corpus NRF2 studies support this pathway

GABA-A receptor potentiation - root constituents (triethylene glycol, withanosides) show GABA-mimetic activity at GABA-A receptors in substantia gelatinosa and hypothalamus; proposed anxiolytic and sleep-promoting mechanism; preclinical evidence only

Co-primary

Safety summary

These are the reasons this compound can still break trust if the protocol fit is otherwise attractive.

Ashwagandha increases serum T3 and T4 levels in clinical trials via thyroid stimulation; additive effect with exogenous thyroid hormone replacement may precipitate hyperthyroidism or thyrotoxicosis

Pregnancy (all trimesters)

Supporting context

Evidence scope

Read these caveats before assuming the effect sizes generalize cleanly across every population or use case.

Generalizability

Review

Hedge effect size estimates for European/North American patients; prefer independent replication data where available

Funding / COI

Review

Apply 20-30% discount to pooled effect sizes from industry-funded pools; prioritize outcomes with independent replication

Evidence scope

Review

Screen for thyroid disease before initiating; monitor TSH at baseline, 8 weeks, and 6 months; contraindicate in hyperthyroidism; exercise caution in Hashimoto's patients

Evidence scope

Review

Do not rely solely on cortisol as surrogate for stress benefit; use validated patient-reported instruments (PSS, STAI) as primary outcomes in clinical use

Synergies

Potential pairing logic is useful only when it adds a cleaner decision path, not when it becomes an excuse to stack indiscriminately.

No validated pairing data yet

Declared

No dossier-backed pairing evidence is currently mapped for Ashwagandha.

Research unknowns

These are the open questions that still keep the compound from reading like a closed case.

Does ashwagandha suppress cortisol at the hypothalamic (CRH), pituitary (ACTH), or adrenal level - and is the mechanism reversible upon discontinuation?

What is the relative contribution of withanolide glycosides vs. aglycones (withaferin A, withanolide A) to clinical efficacy, and are the same metabolites responsible for both therapeutic and hepatotoxic effects?

What are the pharmacokinetic parameters of ashwagandha withanolides in females, and do hormonal cycle phase or menopausal status alter absorption, metabolism, or clearance?

Do ashwagandha's cortisol-lowering and testosterone-elevating effects replicate in African, East Asian, and European populations with ethnicity-stratified analysis?